Compare IDEXX Laboratories, Inc. (IDXX) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Vale SA — how do they compare? IDEXX Laboratories, Inc. trades at $575.81 (market cap $46.22B), while Vale SA trades at $14.43 (market cap $61.97B). The key difference: Vale SA is the larger of the two by market cap, and Vale SA pays a 8.35% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | VALE | |
|---|---|---|
Market Cap | $46.22B | $61.97B |
Sector | Health | Basic Materials |
52-Week High | $766.68 | $17.82 |
52-Week Low | $526.44 | $9.71 |
Enterprise Value | $47.12B | $78.22B |
Dividend Yield | — | 8.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $595.76, up 1.55% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $4.27 versus $3.94 expected, driven by 9% organic revenue growth. The company raised full-year EPS guidance to $14.69–14.94, reflecting robust demand in companion animal diagnostics. Valuation ratios remain elevated with a P/E of 41.23, supported by high profitability margins including a net income margin of 25.03% and ROE of 74.21%.
Outlook is positive given consistent earnings beats, international expansion, and product innovation, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $683.33 implies 14.7% upside, with 57% of analysts rating it Buy. Investors should weigh growth durability against high multiples.
Vale S.A. (VALE) trades at $14.89, up 1.22% today, with a neutral technical stance. The company reported Q2 2026 EPS of $0.36, missing estimates of $0.41, continuing a trend of earnings misses. Revenue for 2025 was $38.40B, with net income margin at 5.11%. Cash flow from operations remains strong at $8.80B for 2025, supporting a $0.40 dividend scheduled for payment in September 2026.
The outlook is mixed: analyst consensus price target is $16.79 (12.8% upside), but rising costs and earnings misses pose risks. Base metals growth offers opportunity, yet iron ore volatility and debt increases require monitoring. The stock presents value with a P/E of 28.64 and EV/EBITDA of 7.65, but investor caution is warranted given recent performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
